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SUMMARY
Purpose: To monitor safety of oxcarbazepine, prescribed
in primary care in England, using prescription-eventmoni-
toring (PEM).
Methods: Postmarketing surveillance using observational
cohort technique of PEM. Exposure data were obtained
from dispensed British National Health Service prescrip-
tions issued by general practitioners (GPs) March 2000–
July 2003. Demographic, drug utilization, and clinical
event data were collected from questionnaires posted to
GPs at least 6months after first prescription date for each
patient. Incidence densities (IDs) (number of first reports
per 1,000 patient-months of treatment) were calculated
and differences for events reported in month 1 (ID1) and
months 2–6 (ID2–6) (99% confidence intervals) were
examined for changes in event rates. Follow-up and cau-
sality assessment of medically significant events were
undertaken.
Results: The cohort comprised 2,243 patients [mean age
40.4 years; range 2–99 years; standard deviation (SD)
18.8; 46.3% (n = 1,038) male]. Most frequently reported
primary indications were epilepsy, convulsion (n = 1,111;
49.5%, n = 209; 9.3%, respectively). GPs recorded 932 rea-
sons for stoppingmedication in 698 (31.1%) patients; most
frequent clinical reason ‘‘drowsiness/sedation’’ (n = 57;
2.5% of cohort). Clinical events (excluding indication)
associated with starting treatment (lower 99% CI > 0)
included: ‘‘drowsiness/sedation’’ (ID1-ID2–6 = 14.2), ‘‘nau-
sea/vomiting’’ (ID1-ID2–6 = 13.0), and dizziness (ID1-
ID2–6 = 11.6). Events followed up and assessed as probably
related to oxcarbazepine use included rash (7 of 11) and
hyponatremia (15 of 38).
Discussion: There were no serious adverse drug reactions
reported during this study. Results of the study should be
taken in context with other epidemiologic studies.
KEY WORDS: Oxcarbazepine, Prescription-event moni-
toring, Safety, Adverse drug reactions.
Epilepsy is a common neurologic condition characterized
by unprovoked recurring seizures (National Institute for
Health and Clinical Excellence 2004a,b). The overall inci-
dence in the developed world is 50 cases per 100,000 person
years (excluding febrile convulsions and single seizures)
(MacDonald et al., 2000). The incidence of epilepsy world-
wide is slightly greater in men than women (National Insti-
tute for Health and Clinical Excellence 2004a,b; World
Health Organization, 2005) and can occur at any age, but is
more frequently diagnosed in patients younger than
20 years of age (Parton & Cockerell, 2003) and in those
older than 60 years (Hauser, 1992). The incidence in chil-
dren is now falling, mainly due to improved obstetric care
and infection control. However, incidence in the elderly
population is rising, due to greater longevity and increased
risk of cerebral vascular disease (World Health Organiza-
tion, 2005). Antiepileptic drug (AED) therapy is now widely
available; however, it is reported to be ineffective in pre-
venting seizures in approximately 50% of patients with
chronic epilepsy (Schmidt & Sachdeo, 2000). Seizure con-
trol may vary with the type of epilepsy, with generalized
tonic–clonic (GTC) seizures being more completely con-
trolled than partial seizures. Approximately 70–80% of
GTC seizures are controlled within one year of starting
monotherapy (Stein & Kanner, 2009).
Oxcarbazepine, launched in the United Kingdom in
March 2000, is indicated for the treatment of partial seizures
with or without secondarily GTC seizures in adults and chil-
dren aged six years and older (Novartis Pharmaceuticals,
2009). It may be prescribed as monotherapy or as adjunctive
therapy. Oxcarbazepine, a keto analog of carbamazepine, is
thought to be associated with fewer adverse events (particu-
larly endocrine). Unlike carbamazepine, the metabolism of
oxcarbazepine is not significantly dependent on the
cytochrome P450 pathway (Rambeck et al., 1996).
Oxcarbazepine is rapidly converted by cytosolic enzymes
in the liver to a 10-monohydroxy derivative (MHD), the
primary pharmacologically active metabolite (Tecoma,
1999). Although MHD and carbamazepine share a common
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mechanism of action in blocking sodium channels, they
modulate different calcium channels (Schmidt & Elger,
2004). Furthermore, MHD has much less pronounced and
more selective induction of the P450 enzyme system and is,
therefore, predicted to have fewer adverse events (particu-
larly endocrine) and drug interactions than carbamazepine
(Schmidt & Elger, 2004).
The Drug Safety Research Unit (DSRU) provides a post-
marketing drug surveillance scheme that monitors the safety
of newly marketed medicines during their immediate post-
marketing period in England, using the noninterventional
observational cohort technique of prescription-event moni-
toring (PEM) (Shakir, 2007). Such studies complement the
information regarding safety collected from clinical studies
and spontaneous reporting schemes. PEM is conducted in
accordance with international ethical guidelines (Royal Col-
lege of Physicians of London, 1996; CIOMS-WHO, 2002;
General Medical Council, 2004).
The objective of this study was to monitor the safety of
oxcarbazepine as used by primary care physicians (general
practitioners, GPs) in England.
Methods
An observational cohort study was conducted in England,
using the technique of PEM, described in more detail previ-
ously (Shakir, 2007). The key steps are outlined in Fig. 1.
Between March 2000 and July 2003, exposure data were
collected from dispensed National Health Service prescrip-
tions for oxcarbazepine issued by GPs in England and
supplied in confidence to the DSRU by the Prescription
Pricing Division (a part of the National Health Service Busi-
ness Services Authority). Hospital prescriptions were not
included in this study. At least six months after the initial
prescription, Green Form questionnaires were sent to pre-
scribing GPs requesting information (outcome data) on any
events that had occurred to the patient since starting
oxcarbazepine. The questionnaire sought information on
patient demographics, aspects of drug utilization (indication
for prescribing, start dose, duration, reasons for discontinu-
ing therapy if treatment was stopped, GP opinion on effec-
tiveness, use as monotherapy or adjunctive therapy, other
coprescribed AEDs) and outcome (event) data.
All reported events were entered onto the DSRU database
using the DSRU event dictionary, which has a hierarchical
structure arranged by system-organ class (SOC). The termi-
nology used by the GP (doctor summary term) is grouped
under a ‘‘lower-level’’ term (LLT), which is subsequently
grouped under a broader, ‘‘higher-level’’ term (HLT), which
is then linked to the respective SOC. An event was coded as
a suspected Adverse Drug Reaction (ADR) if the GP speci-
fied on the Green Form that the event was attributable to the
drug. All reported pregnancies were specifically followed
up to ascertain the outcome of pregnancy. If a death was
reported on the Green Form questionnaire but the informa-
tion provided was insufficient to establish the cause of
death, the GP was contacted for further details.
All returned Green Forms were reviewed by a DSRU
research fellow. Rare and serious events (ICH Harmonised
Tripartite Guideline, 2003) were followed up where a more
likely alternative explanation for their occurrence was not
given. Further evaluation was also undertaken of selected
events of interest including: skin reactions (rash, pruritus),
immunologic (allergy, anaphylaxis, Stevens-Johnson syn-
drome, systemic lupus erythematosus), blood dyscrasias,
vision disorders, metabolic disorders (hyponatremia), and
arrhythmia. Follow-up questionnaires were sent to obtain
additional information to enable assessment of causality.
GPs were offered £15 as reimbursement for completing fol-
low-up questionnaires. Individual case reports were
assessed for causality by two research fellows (at least one
medically qualified) at the DSRU, using the criteria of: tem-
porality, pharmacologic plausibility, clinical and pathologic
characteristics, concomitant treatment, re/dechallenge, past
medical history, and exclusion of other causes and graded as
probable, possible, unlikely, or unassessable (Shakir, 2004).
Analysis
Summary statistics for patient demographic and drug uti-
lization characteristics were calculated. Incidence densities
(IDs) (number of first reports of an event/1,000 patient-
months of exposure) were calculated for all events reported
during treatment in the first month after the initial prescrip-
tion for oxcarbazepine was issued (ID1) to detect events that
may have been associated with oxcarbazepine use and
require further evaluation. This process was repeated for
Figure 1.
Key steps involved in the prescription-event monitoring (PEM)
study for oxcarbazepine.
Epilepsia ILAE
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months 2–6 combined (ID2–6) and for the total study period,
IDA. For each reported event, the arithmetic difference
between ID1 and ID2–6 was calculated with a 99% confi-
dence interval (CI) to examine the null hypothesis that the
rate for the event was not increasing or decreasing between
the two time periods. A descriptive qualitative analysis of
selected event data (including causality assessment) was
also undertaken.
Results
Study cohort
Of the 4,434 Green Forms sent, 2,690 (60.7%) were
returned. Of these, 447 (16.6%) were classified as void and
excluded from the study; 48.8% (n = 218) were void
because the patient was no longer registered with the GP.
Therefore, the study cohort comprised 2,243 patients. The
cohort consisted of 46.3% (n = 1,038) male patients and
53.4% (n = 1,199) female patients; for 0.3% (n = 6) the sex
was not specified. The mean age of the cohort was
40.4 years [range 2–99 years; standard deviation (SD)
18.8]. Fifteen children aged 2–5 years were reported to have
started treatment with oxcarbazepine. There were 193
patients aged 65 years or older who were prescribed
oxcarbazepine.
Indication, starting dose, and adjunctive
antiepileptic therapy
The most frequently reported primary indications for
patients treated with oxcarbazepine were epilepsy
(n = 1,111; 49.5% of cohort) and convulsion (n = 209;
9.3% of cohort) (Table 1A). In addition to the licensed indi-
cation of epilepsy, oxcarbazepine was also prescribed for
trigeminal neuralgia (n = 104; 4.6%), neuralgia (n = 44;
2.0%), pain relief (n = 25; 1.1%), multiple sclerosis
(n = 16; 0.7), and neuropathic pain relief (n = 15; 0.7%).
The full list of indications where four or more reports were
received is shown in Table 1A.
Information on starting dose was available for 1,757
patients (70.2% of cohort). A total of 479 patients (21.4% of
cohort; 30.4% of those where starting dose was specified)
were prescribed the recommended starting dose of 600 mg/
day, 377 (16.8% of cohort, 23.9% of those where starting
dose was specified) were prescribed 300 mg/day, and 179
(8.0% of cohort, 11.4% of those where starting dose was
specified) were prescribed 900 mg/day. Thirty-eight
Table 1A. Themost frequently reported primarya indications for oxcarbazepine where the general practitioner
(GP) specified an indicationb
Indication (Primary)
Male Female DK Total
N % N % N % N %
Epilepsy 533 51.4 576 48.0 2 33.3 1,111 49.5
Convulsion 115 11.1 94 7.8 0 – 209 9.3
Neuralgia trigeminal 33 3.2 71 5.9 0 – 104 4.6
Neuralgia 13 1.3 31 2.6 0 – 44 2.0
Epilepsy grand mal 17 1.6 21 1.8 1 16.7 39 1.7
Pain 11 1.1 14 1.2 0 – 25 1.1
Multiple sclerosis 2 0.2 14 1.2 0 – 16 0.7
Neuropathic pain unspecifiedc 5 0.5 10 0.8 0 – 15 0.7
Pain back 4 0.4 6 0.5 0 – 10 0.5
Spasm muscular 4 0.4 3 0.3 0 – 7 0.3
Depression manic 4 0.4 2 0.2 0 – 6 0.3
Mood swings 3 0.3 3 0.3 0 – 6 0.3
Paraesthesia 2 0.2 4 0.3 0 – 6 0.3
Absence Seizure/attack 3 0.3 2 0.2 0 – 5 0.2
Neuralgia postherpetic 2 0.2 3 0.3 0 – 5 0.2
Behavior abnormal 3 0.3 1 0.1 0 – 4 0.2
Epilepsy petit mal 3 0.3 1 0.1 0 – 4 0.2
Mood stabilizing 1 0.1 3 0.3 0 – 4 0.2
Neuropathy diabetic 3 0.3 1 0.1 0 – 4 0.2
Neuropathy peripheral 2 0.2 2 0.2 0 – 4 0.2
Pain limb 2 0.2 2 0.2 0 – 4 0.2
Tuberous sclerosis 4 0.4 0 – 0 – 4 0.2
Otherd 25 2.4 40 3.3 0 – 65 2.9
DK, don’t know.
aAn individual may have up to three prescribing indications recorded from information provided on the Green Form. These are coded within the database as
primary, secondary, and tertiary indications based on the order given by the prescriber on the form (regardless of clinical importance).
bNot Specified: no indication reported on Green Form, n = 542.
cUnspecified refers to events for which there is no specific lower level term in the DSRU dictionary.
dOther includes all other reported indications such as headache (n = 3), neuropathy (n = 3), depression (n = 2), anxiety (n = 1) and schizophrenia (n = 1).
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patients (1.7% of cohort, 2.2% of those where starting dose
was specified) were prescribed a start dose of 2,400 mg/day
or more (the maximum recommended daily dose) and 574
patients (25.6% of cohort, 63.4% of those where starting
dose was specified) were prescribed a start dose of
<600 mg/day (the minimum recommended start dose)
(Fig. 2).
Where specified, oxcarbazepine was used as monothera-
py in 39.6% of patients (731 of 1,846), whereas 68.3% of
patients (1,086 of 1,590) took oxcarbazepine as adjunctive
therapy to 33 other products (either given as proprietary or
generic names). Of 1,718 reports (a patient could have been
taking more than one product), the most commonly used
concomitant AED was lamotrigine (n = 259, 15.1%), fol-
lowed by sodium valproate (n = 254, 14.8%), and phenyt-
oin (n = 192, 11.2%). Nine other AEDs were listed as
concomitant medications, including topiramate, carbamaze-
pine, levetiracetam, gabapentin, tiagabine, vigabatrin, prim-
idone, phenobarbitone, and ethosuximide.
There were 193 patients 65 years or older who were pre-
scribed oxcarbazepine (n = 87 male; n = 106 female). Of
these, 119 were prescribed a dose of 600 mg/day or less and
50 were using oxcarbazepine as adjunctive therapy. The
most frequently reported indications in this age group were
epilepsy (n = 55), trigeminal neuralgia (n = 34), and con-
vulsion (n = 20). In addition, oxcarbazepine was also pre-
scribed in this age group for neuralgia (n = 10) and
neuropathic pain (n = 3) (Tables 1B and 2).
Duration of treatment, effectiveness, and reasons for
stopping
After six months, 1,462 patients (73.2%) whose duration
of treatment was known were still being prescribed ox-
carbazepine. The median duration of treatment—the time
interval between the date the first prescription was issued
and the date oxcarbazepine was stopped (if stopped), or the
date the questionnaire was returned (if not stopped)—was
287 days [interquartile range (IQR) 174; range 155–329).
GPs recorded 932 reasons for stopping oxcarbazepine in
698 (31.1%) patients, although in a further 60 patients
(2.7%) a reason for stopping was not given. The most fre-
quently reported reason for stopping was ‘‘not effective’’ in
262 patients (11.7% of cohort). The most frequently
reported clinical reason for stopping was ‘‘drowsiness/seda-
tion’’ (n = 57; 2.5% of cohort). Where specified in response
to a general question regarding effectiveness (this related to
general improvement in a patient’s condition and not to any
specific parameters), 68.0% (1,061 of 1,561) of GPs stated
Figure 2.
Starting doses of oxcarbazepine.
Epilepsia ILAE
Table 1B. Themost frequently reported primarya
indications for oxcarbazepine in patients 65 years or
older where the general practitioner (GP) specified
an indicationb
Indication (Primary)
Male Female Total
N % N % N %
Epilepsy 24 35.8 31 37.8 55 36.9
Neuralgia trigeminal 10 14.9 24 29.3 34 22.8
Convulsion 11 16.4 9 11.0 20 13.4
Neuralgia 3 4.5 7 8.5 10 6.7
Epilepsy grand mal 4 6.0 1 1.2 5 3.4
Neuralgia postherpetic 1 1.5 2 2.4 3 2.0
Neuropathic pain
unspecifiedc
3 14.9 0 0 3 2.0
Pain 2 3.0 1 1.2 3 2.0
Absence Seizure/attack 2 3.0 0 0 2 1.3
Multiple sclerosis 1 1.5 1 1.2 2 1.3
Neuropathy diabetic 1 1.5 1 1.2 2 1.3
Otherd 5 7.5 5 6.1 10 6.7
aAn individual may have up to three prescribing indications recorded from
information provided on the Green Form. These are coded within the data-
base as primary, secondary, and tertiary indications based on the order given
by the prescriber on the form (regardless of clinical importance).
bNot Specified: no indication reported on Green Form, n = 44.
cUnspecified refers to events for which there is no specific lower level term
in the DSRU dictionary.
dOther includes all other reported indications, such as headache (n = 3),
neuropathy (n = 3), depression (n = 2), anxiety (n = 1) and schizophrenia
(n = 1).
Table 2. Characteristics of patients aged 65 years
or older (n = 193)
N (%)
Sex
Male (% total) 87 (45.0)
Female (% total) 106 (55.0)
Dose
£600 mg/day (% total)a 119 (61.7)
>600 mg/day (% total) 74 (38.3)
Therapy typeb
Mono (% total)a 90 (64.3)
Adjunctive (% total) 50 (35.7)
aPercentage of total where specified.
bTherapy type was not specified in n = 53; sex not specified n = 1.
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that oxcarbazepine was effective, whereas 32.0% (500 of
1,561) stated that it was not.
In patients 65 years or older (n = 193), GPs recorded 51
reasons for stopping oxcarbazepine in 79 patients (26.5%),
although in a further 11 patients (13.9%) a reason for stop-
ping was not given. The most frequently reported clinical
reason for stopping in this age group was hyponatremia
(n = 4). For six patients, the reason for stopping oxcarbaze-
pine was also considered as an ADR by the GP. ADR reports
included drowsiness (n = 2), depression (n = 1), and seda-
tion (n = 1) (Table 3).
Incidence densities and events of interest
The clinical events (excluding indication) with the high-
est IDs in the first month and that occurred significantly
more frequently in the first month compared with months
2–6 combined were: ‘‘drowsiness/sedation’’ (ID1-ID2–6 =
14.22; 99% CI 5.73–22.72), ‘‘nausea/vomiting’’ (ID1-ID2–
6 = 13.00; 99% CI 5.12–22.88), ‘‘malaise/lassitude’’
(ID1-ID2–6 = 11.47; 99% CI 3.79–19.14), ‘‘dizziness’’ (ID1-
ID2–6 = 11.57; 99% CI 4.04–19.10), ‘‘rash’’ (ID1-ID2–6 =
8.54; 99% CI 2.10–14.98), and ‘‘headache/migraine’’
(ID1-ID2–6 = 6.91; 99% CI 0.53–13.28). All of these events
are listed as common or uncommon undesirable events in
the Summary of Product Characteristics (SPC) except for
drowsiness/sedation, which is not specifically listed and
malaise/lassitude for which the synonymous terms somno-
lence and fatigue are listed (Table 4).
Other common clinical events not associated with starting
treatment according to the ID difference statistic but not
specifically listed in the United Kingdom SPC at the time of
this study were: (incidence % of total number of patients)
unsteadiness (1.38%), fall (1.25%), and injury (1.16%).
Uncommon1 unlisted clinical events included: pruritus
(0.89%), sensation abnormal (0.58%), and anxiety (0.58%).
Thrombocytopenia is listed as very rare (incidence <0.01%)
in the United Kingdom SPC, but in this PEM was uncom-
mon, with seven reports received during treatment (inci-
dence 0.31%). Nonclinical drug utilization events (dose
increased, dose decreased) were also associated with
starting treatment.
There were no serious ADRs to oxcarbazepine recorded
(Table 4); drowsiness and sedation were the most frequently
reported ADRs (n = 15). Events attributable to other medi-
cations were examined to detect possible interactions
between oxcarbazepine and specific medicines. A total of
17 ADRs occurred during treatment with oxcarbazepine,
five of which were related to risperidone (ataxia, confusion,
sedation, tremor, and one unspecified) and four to sodium
valproate (headache, thrombocytopenia, tremor, and vision
deteriorated).
Characteristics of patients who had
''drowsiness/sedation'' during the treatment period
The mean age of patients who had ‘‘drowsiness/
sedation’’ during treatment was 45.3 years, whereas for
those who did not have ‘‘drowsiness/sedation’’ the mean
age was 40.2 years. The majority of patients who had
‘‘drowsiness/sedation’’ during treatment were prescribed
the recommended starting dose of 600 mg/day or less
(80%); the mean age of these patients was 42.1 years. The
mean age of patients who were prescribed greater than the
recommended starting dose of 600 mg/day (20%) was
36.7 years. Patients who had drowsiness/sedation were
more likely to have been prescribed a dose of 600 mg/day
or less (v2, p = 0.01). Regardless of whether the patents
had ‘‘drowsiness/sedation’’ during treatment, the majority
of them were using oxcarbazepine as adjunctive therapy
(Table 5).
Clinical events of interest
Events recorded during treatment with oxcarbazepine
and causally assessed as probably related are summarized in
Table 6.
Skin reactions
In the skin SOC there was one report of bullous erup-
tion (1 of 1), one report of pruritus (1 of 18), and seven
reports of rash (7 of 63) assessed as probably related to
oxcarbazepine use. Two of these rashes were reported as
ADRs to the Committee on Human Medicines (CHM).
Table 3. Reasons for stopping and adverse drug
reactions (ADRs) reported in patients aged 65 years
or older (n = 193)
Reason for stopping
(lower level term) N % ADR
Not effective 21 41.2 X
Hyponatremia 4 7.8 X
Dizziness 3 5.9 X
Drowsiness 3 5.9 2
Diarrhea 2 3.9 X
Patient request 2 3.9 X
Rash 2 3.9 X
Sedation 2 3.9 1
Anaphylaxis 1 2.0 X
Condition improved 1 2.0 X
Depression 1 2.0 1
Hospital referrals: neurology 1 2.0 X
Immobility 1 2.0 X
Intolerance 1 2.0 X
Lassitude 1 2.0 X
Malaise 1 2.0 X
No further request 1 2.0 X
Other drug substituted 1 2.0 X
Pain 1 2.0 X
Unspecified side effects 1 2.0 1
Total 51 100.0 6
1Frequency estimates: very common: ‡1/10; common: ‡1/100 to <1/10;
uncommon: ‡1/1,000 to <1/100; rare: ‡1/10,000 to <1/1,000; very rare:
<1/10,000
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For all seven reports of rash that were assessed as
probably related to oxcarbazepine use, the patients were
using concomitant medications (five of whom were using
concomitant AEDs). Of note, two cases of rash and the
one case of pruritus were associated with a dose increase,
and all events occurred within the first two months of
starting treatment. There were no reports of Stevens-
Johnsons syndrome during this study.
Immunologic reactions
Within the immunologic SOC, there was one case each of
anaphylaxis (1 of 1) and allergy (1 of 5) assessed as proba-
bly related to oxcarbazepine. Both cases appeared to be
associated with a dose increase.
Blood dyscrasias
Within the hemopoietic SOC, none of the cases of neutro-
penia, leukopenia, or thrombocytopenia followed were
assessed as probably related to use of oxcarbazepine.
Vision disorders
Within the eye SOC, there were two cases of visual dis-
turbance (2 of 23) and one case of diplopia (1 of 44)
assessed as probably related to oxcarbazepine. In all three
Table 4. Incidence densities (IDs) ranked for oxcarbazepine in order of ID1 for all events where ID1 ‡3
Higher term N1 N2–6 ID1 ID2–6 ID1-ID2-6 CI min CI max NA (%) IDA RFS ADR
Dose increased 95 104 49.22 12.91 36.30 22.90 49.71 278 (12.4) 15.30 – –
Convulsion, epilepsy 81 102 41.96 12.66 29.30 16.87 41.73 247 (11.0) 13.59 41 2
Not effective 40 133 20.72 16.51 4.21 –5.00 13.42 270 (12.0) 14.86 262 –
Drowsiness, sedation 38 44 19.69 5.46 14.22 5.73 22.72 103 (4.6) 5.67 57 15
Nausea, vomiting 33 33 17.10 4.10 13.00 5.12 20.88 75 (3.3) 4.13 23 6
Malaise, lassitude 31 37 16.06 4.59 11.47 3.79 19.14 83 (3.7) 4.57 44 9
Dizziness 30 32 15.54 3.97 11.57 4.04 19.10 74 (3.3) 4.07 31 4
Dose reduced 27 51 13.99 6.33 7.66 0.36 14.95 131 (5.8) 7.21 – –
Rash 22 23 11.40 2.86 8.54 2.10 14.98 60 (2.7) 3.30 32 5
Headache,migraine 21 32 10.88 3.97 6.91 0.53 13.28 62 (2.8) 3.41 21 3
Visual defect 20 37 10.36 4.59 5.77 )0.51 12.04 73 (3.3) 4.02 26 5
Hospital referrals no
admission
16 31 8.29 3.85 4.44 )1.19 10.07 70 (2.1) 3.85 26 –
Unspecified side effects 16 24 8.29 2.98 5.31 )0.25 10.87 56 (2.5) 3.08 51 56
Electrolyte abnormal 15 29 7.77 3.60 4.17 )1.28 9.62 67 (3.0) 3.69 30 1
Nonsurgical admissions 14 22 7.25 2.73 4.52 )0.69 9.73 56 (2.5) 3.08 9 –
Ataxia 10 9 5.18 1.12 4.06 )0.26 8.39 20 (0.8) 1.10 7 3
Condition improved 8 13 4.14 1.61 2.53 )1.41 6.48 31 (1.4) 1.71 20 –
Intolerance 8 5 4.14 0.62 3.52 )0.32 7.36 18 (0.8) 0.99 17 3
Unsteadiness 8 14 4.14 1.74 2.41 )1.55 6.36 29 (1.4) 1.60 6 3
Confusion 7 18 3.63 2.23 1.39 )2.39 5.17 37 (1.7) 2.04 15 5
Fall 7 10 3.63 1.24 2.38 )1.29 6.06 28 (1.3) 1.54 2 1
Depression 6 25 3.11 3.10 0.00 )3.63 3.64 42 (2.1) 2.31 7 4
Patient request 6 8 3.11 0.99 2.12 )1.28 5.51 22 (1.0) 1.21 22 –
Pruritus 6 10 3.11 1.24 1.87 )1.55 5.29 20 (0.8) 1.10 8 1
Tremor 6 2 3.11 0.25 2.86 )0.44 6.16 11 (0.5) 0.61 5 2
N1, Total number of reports of each event during the first month of treatment; N2–6, Total number of reports of each event during treatment in months 2–6;
ID1, Incidence density for each event during the first month of treatment; ID2–6, Incidence density for each event during treatment months 2–6; ID1-ID2-6, Arith-
metic difference between ID1 and ID2-6; 99% CI, 99% confidence intervals for ID1-ID2–6; NA (%), Total number of reports of each event (% incidence in total
cohort) during total treatment period; IDA, Incidence density for each event for the total treatment period; RFS, reason for stopping oxcarbazepine (total no.
reports = 932 in 698 patients (31.1% of cohort); ADR, adverse drug reaction (total no. reports = 158 in 105 patients (4.7% of cohort). CI, confidence interval.
Significant values are shown in bold.
Table 5. Characteristics of patients who had and did
not have drowsiness/sedation during treatment with
oxcarbazepine
Drowsiness/
sedation (No.
patients = 100)
No drowsiness/
sedation (No.
patients=2143) p-value
Age
Mean (SD)
[Median (range)]
45.3 (20.2)
[47 (2–99)]
(n = 76)
40.2 (18.8)
[39 (2–99)]
(n = 1,595)
t-test, p = 0.99
Sexa
Male (% total) 42 (42.4) 996 (46.6) v2, d.f.(1), p = 0.42
Female (% total) 57 (57.6) 1,142 (53.4)
Dose
£600 mg/day
(% total)b
80 (80.0) 1,459 (68.1) v2, d.f.(1), p = 0.01
>600 mg/day
(% total)
20 (20.0) 684 (31.9)
Therapy typec
Mono (% total) 29 (35.8) 702 (40.4)
Adjunctive
(% total)
52 (64.2) 1,034 (59.6) v2, d.f.(1), p = 0.41
aSex not specified n = 1.
bmean age in patients who were prescribed £600 mg/day = 42.1;
>600 mg/day = 36.7.
cTherapy type was not specified n = 19.
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cases, the events appeared to be associated with a dose
increase.
Hyponatremia
Within the metabolic and endocrine SOC there were 15
(15 of 62) reports of hyponatremia assessed as probably
related to oxcarbazepine use. Of note, in five patients the
event was associated with a dose increase, and four patients
had a previous history of hyponatremia while taking carba-
mazepine.
Arrhythmia
Within the cardiovascular SOC, there were no reports of
disorders of heart rate assessed as probably related to ox-
carbazepine use.
Pregnancies
Five pregnancies were reported during the study period.
In four cases, fetal exposure occurred during the first trimes-
ter and in the remaining case exposure occurred during the
third trimester only. The outcomes of the pregnancies were
five live births with no major structural abnormalities. One
of these five babies was born with positional talipes, which
is not considered a major malformation.
Deaths
A total of 38 deaths (1.7% of cohort) were reported by
GPs during this study. For nine patients, no cause of death
was established. Themost frequently reported cause of death
was malignancy (eight deaths; 20.5% of all reported deaths).
Discussion
This PEM study provides a descriptive and quantitative
analysis of a population prescribed oxcarbazepine under
primary care conditions in England and a summary of the
events reported during use.
Cohort characteristics
This study examined the ‘‘real life’’ use in 2,243 patients
of oxcarbazepine prescribed by GPs in England. Oxcarbaze-
pine is indicated for the treatment of partial seizures with or
without secondarily GTC seizures in adults and children
aged six years and older (Novartis Pharmaceuticals, 2009).
This cohort has demographic characteristics similar to those
in postmarketing studies reported elsewhere (Pauletto &
Bergonzi, 2006; Freidel et al., 2007). Oxcarbazepine is not
recommended for use in children younger than six years of
age; however, in this PEM study there were 15 children
younger than six who were prescribed oxcarbazepine.
Serdaroglu et al., 2003 reported findings from an open-label
nonrandomized multicenter prospective study investigating
the use of oxcarbazepine for the treatment of epilepsy in
children (Serdaroglu et al., 2003). The author reported that
seven children aged between four and six years were
enrolled and the most common adverse event reported was
drowsiness (Serdaroglu et al., 2003). In this PEM study,
there was one ADR reported: ‘‘toxicity’’ in a five-year-old
child, which was not reported to the CHM. Overall,
oxcarbazepine was generally well tolerated in this age
group.
The incidence of epilepsy is increasing in the elderly
population (World Health Organization, 2005). Control of
seizures is important in the elderly due to propensity for
prolonged seizures and increased risk of head trauma and
fracture (Kutluay et al., 2003). Elderly patients are more
likely to experience adverse events following treatment with
AEDs, mainly due to concomitant medications and age-
related reduction in hepatic and renal clearance (Kutluay
et al., 2003).
Oxcarbazepine has been reported to be a reasonable
choice for older patients because it has decreased risk
of drug interactions and adverse events compared with
carbamazepine (Kalis & Huff, 2001). In this study, there
were 193 patients 65 years or older who were prescribed
oxcarbazepine. Safety and tolerability of oxcarbazepine has
previously been demonstrated in elderly patients, with the
profile of adverse events being similar to the profile
observed in adults (Kutluay et al., 2003). In this PEM study,
there were six ADRs reported in oxcarbazepine elderly
patients (including dizziness, drowsiness, and depression).
The most frequently reported indication in this age group
was epilepsy (n = 55). In addition, oxcarbazepine was also
prescribed for neuralgia and neuropathic pain. In elderly
patients, these indications were more frequently reported
than in the general population of patients prescribed
oxcarbazepine during this study. Oxcarbazepine has
previously been used in the effective treatment of these
conditions (Dogra et al., 2005). Where known, the majority
of elderly patients were prescribed oxcarbazepine as mono-
therapy (47%). An epilepsy study conducted in Denmark
revealed the majority of elderly patients also received
oxcarbazepine as monotherapy (Friis et al., 1993). The most
frequently reported reason for stopping oxcarbazepine in
this study was hyponatremia (n = 4). Elderly patients may
be more susceptible to hyponatremia due to concomitant
use of natriuretic medications.
Use of oxcarbazepine
The most frequently reported indications for prescribing
oxcarbazepine were the licensed indications, epilepsy
(49.5%) and convulsion (9.3%). However, oxcarbazepine
was also prescribed outside the terms of license for a range
of other conditions including pain control and mood dis-
orders. Oxcarbazepine has previously been used off-label
for analgesic purposes (Pappagallo, 2003). Due to its mech-
anism of action in blocking sodium and calcium channels,
the hyperexcitability of damaged peripheral nerves is
reduced (Carrazana & Mikoshiba, 2003). Furthermore, evi-
dence has been accumulating regarding the effectiveness of
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oxcarbazepine for the treatment of neuropathic pain, with
fewer adverse events and drug interactions reported than
standard treatments (Zakrzewska & Patsalos, 2002; Carraz-
ana & Mikoshiba, 2003; Pappagallo, 2003). Newer AEDs,
such as oxcarbazepine, have also been used effectively in
the treatment of mood disorders and schizophrenia (Hosak
& Libiger, 2002; Evins, 2003).
The efficacy of oxcarbazepine in the treatment of epi-
lepsy has been proven in randomized controlled trials (Bill
et al., 1997; Christe et al., 1997; Guerreiro et al., 1997;
Schachter et al., 1999a,b; Novartis Pharmaceuticals, 2009).
Efficacy of oxcarbazepine is thought to be maintained
throughout prolonged therapy. In this PEM investigation, at
the end of six months of treatment, approximately three-
fourths (73.1%) of patients were still using oxcarbazepine;
the mean duration of treatment being 273 days (39 weeks).
This is similar to the average duration of follow-up reported
for some randomized controlled trials (48–50 weeks), with
the majority of patients completing the studies (Reinikainen
et al., 1987; Dam et al., 1989). Regarding perception of
effectiveness, in this PEM study, there were 1,061 patients
(68.0%) for whom the GPs thought oxcarbazepine was
effective.
Events of interest
Several methods are applied in PEM in order to identify
events that may be associated with oxcarbazepine use,
including examining reports of ADRs and reasons for stop-
ping the study drug, analysis of event rates or risks during
treatment, and assessment of important medical events. The
most frequently reported ADRs to oxcarbazepine during
this study were drowsiness/sedation, malaise/lassitude, nau-
sea/vomiting, confusion, and rash, which were also among
the most frequently reported reasons for stopping. Of the
nine events associated with the first month of treatment, one
was indication-related (convulsion/epilepsy) and six were
clinical events (drowsiness/sedation, nausea/vomiting, mal-
aise/lassitude, dizziness, rash, headache, migraine) which
are listed in the SPC as common or very common events
(Novartis Pharmaceuticals, 2009). Events such as dose
increased and dose reduced also occurred more frequently
in the first month compared with months two to six. This
information may illustrate the utilization pattern in patients
with epilepsy. A significant difference in dose increased in
the first month may be reflective of the requirement to titrate
the dose to a maximum of 2,400 mg/day where necessary
(Novartis Pharmaceuticals, 2009).
Central nervous system–related adverse events are asso-
ciated with oxcarbazepine used as monotherapy or adjunc-
tive therapy, and ‘‘sedation’’ has been reported in other
observational studies (Wellington & Goa, 2001). Our unex-
pected observation of drowsiness/sedation being associated
with starting treatment may possibly be explained by mis-
classification of events, given that somnolence is a com-
mon listed event. The mean age of the patients who had
drowsiness/sedation during treatment was 45 years,
whereas it was 40 years in patients who did not have
drowsiness/sedation. The occurrence of drowsiness/seda-
tion seemed to be associated with a dose of 600 mg/day or
less (v2, p = 0.01); however, the mean age of these patients
was slightly older (42 years compared to 37 years for those
on a dose of 600 mg/day or more), which may account for
the increase in drowsiness/sedation. In addition, the major-
ity of patients who had drowsiness/sedation were using ox-
carbazepine as adjunctive therapy. Other AEDs also
possess sedative properties and may act in synergy with ox-
carbazepine, culminating in an increased risk of drowsi-
ness/sedation. Daytime sedation has particular implications
on the elderly as they are a greater risk of injury from falls
or other accidents (Punjabi & Haponik, 2000). This sup-
ports our observations of fall and injury reported as com-
mon events during treatment.
Cutaneous adverse reactions to AEDs are common; how-
ever, these reactions are thought to occur more frequently in
older AEDs such as carbamazepine (Walia et al., 2004). It is
has been reported that between 5% and 20% of patients dis-
continue AEDs because of adverse events, including skin
hypersensitivity reactions (Troost et al., 1996). Hypersensi-
tivity and serious skin reactions form the basis of special
warnings and precautions for use, recommended since 2005
(after data collection for this study was completed) (Novar-
tis Pharmaceuticals 2005, 2009). Oxcarbazepine has been
shown to increase the risk of adverse cutaneous reactions
(Warnock &Morris, 2003). Cutaneous reactions during this
study include rash being associated with starting treatment,
given frequently as a reason for stopping, and seven cases
assessed as probably related to oxcarbazepine. Further
examination of these assessed events identified an associa-
tion with older age (median age 53), dose, and concomitant
AED use. One of these patients also had a past history of
allergy to carbamazepine. The manufacturer advises that the
use of oxcarbazepine in such patients should be carefully
considered (Novartis Pharmaceuticals, 2009). AED-related
rash has previously been associated with increasing age and
concomitant medication (Alvestad et al., 2007). Decreasing
metabolism and liver function are thought to contribute to
this association (Alvestad et al., 2007). In addition to rash,
there was one report each of other skin reactions (bullous
eruption and pruritus) and of hypersensitivity reactions
(allergy and anaphylaxis), all assessed as probably related to
oxcarbazepine. Because of its pharmacologic structure,
such reactions are thought to occur less frequently with
oxcarbazepine than with other AEDs (Schmidt & Sachdeo,
2000).
With regard to cardiac arrhythmias, during this study
there were no reports of disorders of heart rhythm and only
one report of tachycardia during treatment (no response to
follow-up). In addition, there were nine reports of palpita-
tion during treatment, one of which was assessed as proba-
bly related to oxcarbazepine use. Recommendations
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included in the SPC suggest that patients with cardiac insuf-
ficiency and secondary heart failure should be monitored
regularly (Novartis Pharmaceuticals, 2009). In addition,
patients with preexisting cardiac conduction disturbances
may be more susceptible to impairment in their cardiac con-
duction and should be observed closely while using
oxcarbazepine (Novartis Pharmaceuticals, 2009).
Visual field defects have been widely associated with the
use of AEDs, particularly vigabatrin (Wilton et al., 1999;
Wong & Lhatoo, 2000). Visual disturbance has previously
been reported with oxcarbazepine use (Novartis Pharma-
ceuticals, 2009). In this study, there were two reports of
visual disturbance and one report of diplopia assessed as
probably related to oxcarbazepine; all three events appeared
to be associated with a dose increase.
AED treatment is a well-documented cause of hyponatre-
mia, (Mavragani & Vlachoyiannopoulos, 2005) and is listed
as a common undesirable effect in the SPC (Novartis Phar-
maceuticals, 2009). Serum sodium levels in patients with
preexisting renal impairment or patients being treated with
sodium-lowering agents should be measured prior to treat-
ment initiation with oxcarbazepine and then again after two
weeks. It is recommended monitoring should continue at
monthly intervals for three months (Novartis Pharmaceuti-
cals, 2009). In this study there were 63 reports of hyponatre-
mia, 15 of which were assessed as probably related to
oxcarbazepine use. Four of these patients had previously
experienced hyponatremia while taking carbamazepine. In
addition, 13 of these patients were female. Previous studies
have suggested that there may be gender-related differences
in sodium metabolism, with female patients being more sus-
ceptible than male patients. The median age of these
patients was 52, and 13 of these patients were taking con-
comitant medications. Potential risk factors for the develop-
ment of hyponatremia in patients using psychotropic
medications include female gender, increasing age, and con-
comitant medications known to cause hyponatremia (Son-
nenblick et al., 1993; Madhusoodanan et al., 2002). The
mechanism by which oxcarbazepine exerts its effects on
serum sodium levels is thought to be dose dependent (Shor-
von, 2000). In this study, of the reports of hyponatremia
assessed as probably related to oxcarbazepine, four patients
started taking >600 mg/day (the recommended starting
dose). It has been recommended that hyponatremia in
patients taking oxcarbazepine should be managed through
water restriction and if necessary treatment withdrawal
(Smith, 2001). In this study, treatment was discontinued
in 11 of the 15 reports assessed as probably related to
oxcarbazepine.
Fetal safety data are important, given that AEDs are
known teratogens, increasing the risk of major malforma-
tions in newborns of mothers using the drugs by approxi-
mately twofold (Montouris, 2005). Treatment of epilepsy in
pregnancy is complicated. It is important that adequate
seizure control is maintained throughout pregnancy, due to
the potential risk to the fetus during maternal seizures (Mon-
touris, 2005). It is estimated that 3–4 pregnancies per 1,000
occur in women with epilepsy and one in 200 women
attending antenatal clinics are taking AEDs (Epilepsy
Guidelines Group, 2004). Results from this study show no
structural abnormalities; however, there were only five
reported pregnancies.
Strengths and limitations
The strengths and limitations of this study design have
been described in detail elsewhere (Shakir, 2007). PEM is a
noninterventional observational methodology. It does not
influence the prescribing decisions of GPs. This study was
carried out on a national scale, and included patients pre-
scribed oxcarbazepine in everyday clinical practice. This
method is advantageous over pre- and postmarketing clini-
cal trials, which usually comprise a select population of
patients. The strict inclusion and exclusion criteria applied
in controlled clinical trials were not applied in this PEM
study. As a result, this study provided information regarding
use of oxcarbazepine in general practice in England, irre-
spective of age, past medical history, or concomitant medi-
cation.
In requesting the prescribing GP to supply data on
‘‘events’’ experienced by the patient, this study had the
potential of identifying safety signals that were not neces-
sarily suspected as being ADRs to oxcarbazepine. Medi-
cally important events were followed up, which facilitated a
more detailed understanding of confounders, biases, and
outcomes of events.
PEM collects information on large cohorts of patients
(frequently more than 10,000) prescribed newly marketed
medications in general practice. PEM does not include hos-
pital prescriptions. Data include health-related events
recorded in the patients’ notes after treatment with the drug
being monitored. This provides reliable exposure denomi-
nators and minimizes recall bias. This study comprised
2,243 patients. Although the final cohort was small when
compared with previously reported PEM studies (median
11,543; IQR 9,089–13,665) (Davies et al., 2008), this num-
ber is higher than the number enrolled in clinical trials for
oxcarbazepine (Beydoun, 1997, 2000; Glauser et al., 2000).
The cohort size reflects the rate GPs prescribed oxcarbaze-
pine for new treatment initiations in England during the
study period.
As with all other observational studies, PEM lends itself
to inherent weaknesses in the study design. One of these
weaknesses may be the response rate. Of the Green Forms
sent (n = 4,434), 2,690 (60.9%) were returned. This study
did not assess the impact of nonresponse bias. However, the
response rate is comparable to response rates reported else-
where for GP postal surveys (McAvoy & Kaner, 1996), but
is slightly higher than the average response rate of 56.3%
for the 100 other PEM studies completed by the DSRU. Of
the Green Forms that were returned, 16.6% of them were
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classified as void; the main reason for exclusion (49%) was
because the patient was no longer registered at the practice.
It is difficult to estimate accurately the exact rate of patient
migration between GP practices; however, the latest figures
available from the office of national statistics suggest a net
increase in both interregional and international migration in
the United Kingdom (Office of National Statistics, 2006).
Therefore, it is reasonable to expect that a number of
patients will have moved GP practice during the course of a
PEM study.
Compliance with treatment cannot be measured (as
with most observational pharmacoepidemiologic studies),
and this may lead to an underestimate of the measure of
effect, or to a false conclusion regarding any possible
associations between the drug and any outcomes. Lastly,
the study may be biased due to underreporting of events
by GPs (including serious and fatal events). However,
because PEM is based on the reporting of ‘‘events’’ rather
than suspected ADRs, it is at least as likely as spontane-
ous reporting systems (such as the yellow-card scheme) to
detect ADRs (Martin et al., 1998). Previous studies have
shown that reporting in PEM is higher than spontaneous
reporting for both serious and nonserious ADRs (Martin
et al., 1998). Therefore, PEM and spontaneous reporting
are complementary in studying the postmarketing safety
of medicinal products.
PEM does not collect information on patients whose
treatment was initiated and stopped in secondary care, and
therefore this methodology cannot detect adverse events
that occurred while the patients’ treatments were being
monitored in secondary care.
Conclusions
This study examined the postmarketing safety of ox-
carbazepine in 2,243 patients when used in general clinical
practice in England. The most frequently reported ADRs to
oxcarbazepine in this study were drowsiness/sedation, mal-
aise/lassitude, nausea/vomiting, confusion, and rash. There
were no serious ADRs reported for oxcarbazepine during
this study.
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